BOUNTIFUL, Utah--Specialized Health Products(R) International, Inc. (OTCBB: SHPI), a leader in the design and development of medical safety needles, today announced its wholly-owned subsidiary, Safety Syringe Corporation, has received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) to marke
CHICAGO--Web-based, Point-of-Care, Decision-Support System to Assist Clinicians Treating HIV; System Delivers Therapy Options, Based on Patient Data and the Latest Clinical Research TherapyEdge(TM), Inc., developer and provider of cutting-edge, point-of-care decision support systems for individualized patient care, tod
CHICAGO--Responding to the need for HIV treatments that work against the virus in a new way, scientists and clinicians are gathering this week at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held here December 16-19, 2001, to review the latest research on entry inhibitors.
SANTA MONICA, Calif. & PARIS--Specialty Expands its Comprehensive Suite of HIV Testing to Become First Full Service Laboratory Offering In-House Phenotyping Specialty Laboratories, Inc. (NYSE:SP) (Specialty), a leading research-driven clinical reference laboratory, and VIRalliance, a subsidiary of BioAlliance, The
LOS ANGELES--(BW HealthWire)--The Ministry of Health/Government of Uganda , the Ugandan Business Coalition on HIV/AIDS and AIDS Healthcare Foundation Global Immunity Join Forces in Uganda Cares, a New AIDS Treatment Initiative AHF Global Community (AHF GI), an international initiative of AIDS Healthcare Foundation, tod
PHILADELPHIA -- Independent Research Also Suggests Serious Side Effects Of Smallpox Vaccine May Also Be Reduced; Company Continuing Advanced Clinical Trials in HIV/AIDS And Chronic Fatigue Syndrome Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the development of immune based therapies primarily addressing
LEXINGTON, Mass. -- International Association of Physicians in AIDS Care Presents Overview of Treatment Paradigm Shift Signaled by the Latest Revisions of the DHHS Guidelines Centra (NASDAQ: CTRA), the leading provider of software infrastructure and ASP services for eLearning and real-time business collaboration, today
VANCOUVER, B.C.-- Immune Network Ltd. (OTCBB:IMMKF)(CDNX:IMM) announced today it has granted a sublicense option to InNexus Corporation of Seattle for the application of SuperAntibody technology to Immune Network s monoclonal antibodies hNM01 and 1F7. InNexus is focused on the use of SuperAntibodies, a new technology t
NEW YORK -- Luncheon Honors UK Physician Dame Cicely Saunders and St. Christopher s Hospice Recipient of 2001 Hilton Humanitarian Prize At an award luncheon that was Web cast live (video and audio) from the Hilton Web site www.hiltonfoundation.org, UN Secretary General Kofi Annan called for an expansion of hospice worl
SUNNYVALE, Calif. and NEW YORK--(BUSINESS WIRE)--Nov. 29, 2001-- When people log onto Yahoo!(R) Messenger (http://messenger.yahoo.com) during December, they can help in the global effort to find a vaccine for AIDS. As part of worldwide recognition of World AIDS Day on December 1, Yahoo! Inc. (Nasdaq:YHOO), a leading gl
SUNNYVALE, Calif. and NEW YORK--(BUSINESS WIRE)--Nov. 29, 2001-- When people log onto Yahoo!(R) Messenger (http://messenger.yahoo.com) during December, they can help in the global effort to find a vaccine for AIDS. As part of worldwide recognition of World AIDS Day on December 1, Yahoo! Inc. (Nasdaq:YHOO), a leading gl
WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 29, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced
WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 29, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced
ALAMEDA, Calif.--(BW HealthWire)--Nov. 23, 2001--Calypte Biomedical Corp. (OTCBB:CALY) today announced it has signed a key agreement with San Antonio-based SA Scientific Inc., a privately held company, to develop a new urine-based rapid HIV-1/2 antibody test that can provide results in as little as 15 minutes. Our expa
ALAMEDA, Calif.--(BW HealthWire)--Nov. 23, 2001--Calypte Biomedical Corp. (OTCBB:CALY) today announced it has signed a key agreement with San Antonio-based SA Scientific Inc., a privately held company, to develop a new urine-based rapid HIV-1/2 antibody test that can provide results in as little as 15 minutes. Our expa
ALAMEDA, Calif.--(BW HealthWire)--Nov. 23, 2001--Calypte Biomedical Corp. (OTCBB:CALY) today announced it has signed a key agreement with San Antonio-based SA Scientific Inc., a privately held company, to develop a new urine-based rapid HIV-1/2 antibody test that can provide results in as little as 15 minutes. Our expa
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 20, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that its subsidiary, Biosystems Technologies, Inc., has signed an exclusive agreement for clinical trials and distribution of a new herbal product believed to be effective in the treatment of viral Hepatit
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 20, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that its subsidiary, Biosystems Technologies, Inc., has signed an exclusive agreement for clinical trials and distribution of a new herbal product believed to be effective in the treatment of viral Hepatit
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 20, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that its subsidiary, Biosystems Technologies, Inc., has signed an exclusive agreement for clinical trials and distribution of a new herbal product believed to be effective in the treatment of viral Hepatit
PASADENA, Calif.--(BW HealthWire)--Nov. 15, 2001--ViaLogy Corp. today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 6,245,511, titled Method and Apparatus for Exponentially Convergent Therapy Effectiveness Monitoring Using DNA Microarray-Based Viral Load Measurements, which has been assigne
PASADENA, Calif.--(BW HealthWire)--Nov. 15, 2001--ViaLogy Corp. today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 6,245,511, titled Method and Apparatus for Exponentially Convergent Therapy Effectiveness Monitoring Using DNA Microarray-Based Viral Load Measurements, which has been assigne
PASADENA, Calif.--(BW HealthWire)--Nov. 15, 2001--ViaLogy Corp. today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 6,245,511, titled Method and Apparatus for Exponentially Convergent Therapy Effectiveness Monitoring Using DNA Microarray-Based Viral Load Measurements, which has been assigne
ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organiz
ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organiz
ALAMEDA, Calif.--(BW HealthWire)--Nov. 14, 2001--Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organiz
ALAMEDA, Calif. -- Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-appro
ALAMEDA, Calif. -- Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-appro
ALAMEDA, Calif. -- Calypte Biomedical Corporation (OTCBB:CALY) announced today that Planned Parenthood Mar Monte (San Jose) has added Calypte s urine HIV-1 tests as an alternative for its clients being tested for HIV. Planned Parenthood Mar Monte, a member of the Planned Parenthood organization, has the only CLIA-appro
NEWTOWN, Pa.-- State government officials see pharmaceutical spending for chronic diseases as an opportunity to control health care costs. Disease Management Policy Alerts, designed to provide a detailed look at state programs, legislation and regulations affecting chronic diseases, has been launched by Scott-Levin, a
NEWTOWN, Pa.-- State government officials see pharmaceutical spending for chronic diseases as an opportunity to control health care costs. Disease Management Policy Alerts, designed to provide a detailed look at state programs, legislation and regulations affecting chronic diseases, has been launched by Scott-Levin, a
NEWTOWN, Pa.-- State government officials see pharmaceutical spending for chronic diseases as an opportunity to control health care costs. Disease Management Policy Alerts, designed to provide a detailed look at state programs, legislation and regulations affecting chronic diseases, has been launched by Scott-Levin, a
KENMORE, Wash.--(BUSNESS WIRE)--Nov. 13, 2001--Leanna Standish, ND, PhD, LAc, Senior Research Scientist at Bastyr University s Research Institute, is co-editor of a new book from Harcourt International about treating AIDS with complementary and alternative medicine (CAM). AIDS and Complementary and Alternative Therapy
KENMORE, Wash.--(BUSNESS WIRE)--Nov. 13, 2001--Leanna Standish, ND, PhD, LAc, Senior Research Scientist at Bastyr University s Research Institute, is co-editor of a new book from Harcourt International about treating AIDS with complementary and alternative medicine (CAM). AIDS and Complementary and Alternative Therapy
KENMORE, Wash.--(BUSNESS WIRE)--Nov. 13, 2001--Leanna Standish, ND, PhD, LAc, Senior Research Scientist at Bastyr University s Research Institute, is co-editor of a new book from Harcourt International about treating AIDS with complementary and alternative medicine (CAM). AIDS and Complementary and Alternative Therapy
Enzo Biochem, Inc. (NYSE:ENZ), encouraged by results thus far of its Phase 2 study of EHT899, the Company s proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus ( HBV ), said it is planning to launch a multi-centered, double blind, randomized study of the
Enzo Biochem, Inc. (NYSE:ENZ), encouraged by results thus far of its Phase 2 study of EHT899, the Company s proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus ( HBV ), said it is planning to launch a multi-centered, double blind, randomized study of the
Enzo Biochem, Inc. (NYSE:ENZ), encouraged by results thus far of its Phase 2 study of EHT899, the Company s proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus ( HBV ), said it is planning to launch a multi-centered, double blind, randomized study of the
EXTON, Pa.--(BUSINESS WIRE)--Nov. 12, 2001--ViroPharma Incorporated and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation , today announced an update regarding their collaboration to develop treatments for hepatitis C. The companies are engaged in a broad-based discovery resea
EXTON, Pa.--(BUSINESS WIRE)--Nov. 12, 2001--ViroPharma Incorporated and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation , today announced an update regarding their collaboration to develop treatments for hepatitis C. The companies are engaged in a broad-based discovery resea
EXTON, Pa.--(BUSINESS WIRE)--Nov. 12, 2001--ViroPharma Incorporated and Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation , today announced an update regarding their collaboration to develop treatments for hepatitis C . The companies are engaged in a broad-based discovery r
LOS ANGELES--(BUSINESS WIRE)--Nov. 7, 2001--AIDS Healthcare Foundation (AHF), the nation s largest private provider of HIV medical services, announced today that it signed a contract with R & K Pharmacy Services, Inc., an affiliate of Metropolitan Health Networks, Inc., for R & K to provide pharmacy management
LOS ANGELES--(BUSINESS WIRE)--Nov. 7, 2001--AIDS Healthcare Foundation (AHF), the nation s largest private provider of HIV medical services, announced today that it signed a contract with R & K Pharmacy Services, Inc., an affiliate of Metropolitan Health Networks, Inc., for R & K to provide pharmacy management
LOS ANGELES--(BUSINESS WIRE)--Nov. 7, 2001--AIDS Healthcare Foundation (AHF), the nation s largest private provider of HIV medical services, announced today that it signed a contract with R & K Pharmacy Services, Inc., an affiliate of Metropolitan Health Networks, Inc., for R & K to provide pharmacy management
ATLANTA--(BW HealthWire)--Nov. 7, 2001--Atlanta-based National Health Information, LLC, one of the country s leading healthcare publishers, today announced the launch of Bioterror Medical Alert, a twice-monthly newsletter providing doctors and other health professionals with up-to-the-minute news and guidance on the cl
ATLANTA--(BW HealthWire)--Nov. 7, 2001--Atlanta-based National Health Information, LLC, one of the country s leading healthcare publishers, today announced the launch of Bioterror Medical Alert, a twice-monthly newsletter providing doctors and other health professionals with up-to-the-minute news and guidance on the cl
ATLANTA--(BW HealthWire)--Nov. 7, 2001--Atlanta-based National Health Information, LLC, one of the country s leading healthcare publishers, today announced the launch of Bioterror Medical Alert, a twice-monthly newsletter providing doctors and other health professionals with up-to-the-minute news and guidance on the cl
NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2001--Roche and Trimeris (Nasdaq: TRMS) today announced that site selection and patient enrollment will begin in the U.S. for T20-305, an open-label study of the investigational HIV drug T-20 in combination with oral antiretrovirals that will be conducted in Nor
NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2001--Roche and Trimeris (Nasdaq: TRMS) today announced that site selection and patient enrollment will begin in the U.S. for T20-305, an open-label study of the investigational HIV drug T-20 in combination with oral antiretrovirals that will be conducted in Nor
NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2001--Roche and Trimeris (Nasdaq: TRMS) today announced that site selection and patient enrollment will begin in the U.S. for T20-305, an open-label study of the investigational HIV drug T-20 in combination with oral antiretrovirals that will be conducted in Nor
MONTREAL--(BW HealthWire)--Nov. 6, 2001--More than two thirds of the eleven thousand physicians participating in a recent survey said they rely on Internet and/or e-mail medical news services to keep abreast of developments emanating from medical conferences and other large medical meetings they do not attend. Nuvis Wo
MONTREAL--(BW HealthWire)--Nov. 6, 2001--More than two thirds of the eleven thousand physicians participating in a recent survey said they rely on Internet and/or e-mail medical news services to keep abreast of developments emanating from medical conferences and other large medical meetings they do not attend. Nuvis Wo
MONTREAL--(BW HealthWire)--Nov. 6, 2001--More than two thirds of the eleven thousand physicians participating in a recent survey said they rely on Internet and/or e-mail medical news services to keep abreast of developments emanating from medical conferences and other large medical meetings they do not attend. Nuvis Wo
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 5, 2001-- AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-focused Program Aims to Boost Adherence to Medication Regimens Metropolitan Health Networks, Inc. (METCARE(TM))(OTC BB: MDPA) today announced that its pharmacy division, M
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 5, 2001-- AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-focused Program Aims to Boost Adherence to Medication Regimens Metropolitan Health Networks, Inc. (METCARE(TM))(OTC BB: MDPA) today announced that its pharmacy division, M
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 5, 2001-- AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-focused Program Aims to Boost Adherence to Medication Regimens Metropolitan Health Networks, Inc. (METCARE(TM))(OTC BB: MDPA) today announced that its pharmacy division, M
WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 1, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced t
WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 1, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced t
WOODLAND HILLS, Calif.--(BW HealthWire)--Nov. 1, 2001--Amerimmune Pharmaceuticals Inc. (OTCBB:AMUN), a pharmaceutical research company that is developing Cytolin(R), a revolutionary treatment for patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS), today announced t
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 30, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that it has formed a subsidiary to enter into the biotechnology marketplace. The new company, Biosystems Technologies, Inc. is engaged in the commercialization, marketing and distribution of biomedical pro
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 30, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that it has formed a subsidiary to enter into the biotechnology marketplace. The new company, Biosystems Technologies, Inc. is engaged in the commercialization, marketing and distribution of biomedical pro
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 30, 2001--Genesis Technology Group, Inc. (OTCBB:GTEC) announced today that it has formed a subsidiary to enter into the biotechnology marketplace. The new company, Biosystems Technologies, Inc. is engaged in the commercialization, marketing and distribution of biomedical pro
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2001-- Gilead Sciences (Nasdaq:GILD) today announced that it has received U.S. Food and Drug Administration ( FDA ) approval for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human immunodeficiency virus (HIV) infection when
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2001-- Gilead Sciences (Nasdaq:GILD) today announced that it has received U.S. Food and Drug Administration ( FDA ) approval for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human immunodeficiency virus (HIV) infection when
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 26, 2001-- Gilead Sciences (Nasdaq:GILD) today announced that it has received U.S. Food and Drug Administration ( FDA ) approval for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human
EDMONTON, Alberta--(BW HealthWire)--Oct. 24, 2001--Mr. Warren Jackson, President and CEO, is pleased to announce that the company has signed a contract to enter into a joint venture with Erdos Cashmere Group Corporation based in Inner Mongolia , China . The proposed joint venture (JV), subject to all regulatory appr
EDMONTON, Alberta--(BW HealthWire)--Oct. 24, 2001--Mr. Warren Jackson, President and CEO, is pleased to announce that the company has signed a contract to enter into a joint venture with Erdos Cashmere Group Corporation based in Inner Mongolia , China . The proposed joint venture (JV), subject to all regulatory appr
EDMONTON, Alberta--(BW HealthWire)--Oct. 24, 2001--Mr. Warren Jackson, President and CEO, is pleased to announce that the company has signed a contract to enter into a joint venture with Erdos Cashmere Group Corporation based in Inner Mongolia , China . The proposed joint venture (JV), subject to all regulatory appr
KENMORE, Wash.--(BUSINESS WIRE)--Oct. 23, 2001-- Garlic is one of the most common herbs used medicinally by HIV positive individuals. But the question remains: does it work and, in particular, is it an answer to unwanted side effects? The anti-viral cocktail of modern AIDS drugs (also called Highly Active Anti-Retrovir
KENMORE, Wash.--(BUSINESS WIRE)--Oct. 23, 2001-- Garlic is one of the most common herbs used medicinally by HIV positive individuals. But the question remains: does it work and, in particular, is it an answer to unwanted side effects? The anti-viral cocktail of modern AIDS drugs (also called Highly Active Anti-Retrovir
KENMORE, Wash.--(BUSINESS WIRE)--Oct. 23, 2001-- Garlic is one of the most common herbs used medicinally by HIV positive individuals. But the question remains: does it work and, in particular, is it an answer to unwanted side effects? The anti-viral cocktail of modern AIDS drugs (also called Highly Active Anti-Retrovir
LOS ANGELES--(BUSINESS WIRE)--Oct. 19, 2001--Kaire Holdings, Inc. s YesRx Health Advocate Program has been selected by the Los Angeles County Department of Health Services, HIV Epidemiology Program, in Collaboration with the Centers for Disease Control and Prevention to be a primary pharmacy provider for their Directly
LOS ANGELES--(BUSINESS WIRE)--Oct. 19, 2001--Kaire Holdings, Inc. s YesRx Health Advocate Program has been selected by the Los Angeles County Department of Health Services, HIV Epidemiology Program, in Collaboration with the Centers for Disease Control and Prevention to be a primary pharmacy provider for their Directly
LOS ANGELES--(BUSINESS WIRE)--Oct. 19, 2001--Kaire Holdings, Inc. s YesRx Health Advocate Program has been selected by the Los Angeles County Department of Health Services, HIV Epidemiology Program, in Collaboration with the Centers for Disease Control and Prevention to be a primary pharmacy provider for their Directly
MIAMI LAKES, Fla.--(BUSINESS WIRE)--Oct. 18, 2001--World Diagnostics, Inc., www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it received additional approvals and authorization from the Dru
MIAMI LAKES, Fla.--(BUSINESS WIRE)--Oct. 18, 2001--World Diagnostics, Inc., www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it received additional approvals and authorization from the Dru
MIAMI LAKES, Fla.--(BUSINESS WIRE)--Oct. 18, 2001--World Diagnostics, Inc., www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it received additional approvals and authorization from the Dru
SEATTLE--(BW HealthWire)--Oct. 10, 2001--International Therapeutics, Inc. (ITI) announces the establishment of the annual Glenn Kawasaki Humanitarian Award . The award will recognize the efforts of individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management.
SEATTLE--(BW HealthWire)--Oct. 10, 2001--International Therapeutics, Inc. (ITI) announces the establishment of the annual Glenn Kawasaki Humanitarian Award . The award will recognize the efforts of individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management.
SEATTLE--(BW HealthWire)--Oct. 10, 2001--International Therapeutics, Inc. (ITI) announces the establishment of the annual Glenn Kawasaki Humanitarian Award . The award will recognize the efforts of individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management.
VIENNA, Va.--(BUSINESS WIRE)--Oct. 9, 2001--CEL-SCI CORPORATION Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Vi
VIENNA, Va.--(BUSINESS WIRE)--Oct. 9, 2001--CEL-SCI CORPORATION Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Vi
VIENNA, Va.--(BUSINESS WIRE)--Oct. 9, 2001--CEL-SCI CORPORATION Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Vi
SEATTLE--(BW HealthWire)--Oct. 3, 2001--5 Starliving Online Inc. and Viral Genetics Inc. are pleased to announce today that they have closed the acquisition disclosed in the press release dated September 18, 2001. Viral Genetics, Inc., a development-stage California corporation, was founded in 1995 to discover, develop
SEATTLE--(BW HealthWire)--Oct. 3, 2001--5 Starliving Online Inc. and Viral Genetics Inc. are pleased to announce today that they have closed the acquisition disclosed in the press release dated September 18, 2001. Viral Genetics, Inc., a development-stage California corporation, was founded in 1995 to discover, develop
SEATTLE--(BW HealthWire)--Oct. 3, 2001--5 Starliving Online Inc. and Viral Genetics Inc. are pleased to announce today that they have closed the acquisition disclosed in the press release dated September 18, 2001. Viral Genetics, Inc., a development-stage California corporation, was founded in 1995 to discover, develop
SAN ANTONIO--(BW HealthWire)--Oct. 1, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans. HI
SAN ANTONIO--(BW HealthWire)--Oct. 1, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans. HI
SAN ANTONIO--(BW HealthWire)--Oct. 1, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans. HI
ELMWOOD PARK, N.J.--(BW HealthWire)--Sept. 28, 2001-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it will begin marketing the Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test. Visible Genetics Inc. (VGI, NASDAQ: VGIN) announced on Wednesday that it has received clearance from the U.S. Food an
ELMWOOD PARK, N.J.--(BW HealthWire)--Sept. 28, 2001-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it will begin marketing the Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test. Visible Genetics Inc. (VGI, NASDAQ: VGIN) announced on Wednesday that it has received clearance from the U.S. Food an
ELMWOOD PARK, N.J.--(BW HealthWire)--Sept. 28, 2001-- Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it will begin marketing the Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test. Visible Genetics Inc. (VGI, NASDAQ: VGIN) announced on Wednesday that it has received clearance from the U.S. Food an
EDMONTON, Alberta--(BW HealthWire)--Sept. 26, 2001--Warren Jackson, President and Chief Executive Officer of Edmonton-based Altachem Pharma Limited, today announced the successful completion of the formal acquisition of 100% of the world rights to develop, manufacture and sell Bionex(TM), a revolutionary compound desig
EDMONTON, Alberta--(BW HealthWire)--Sept. 26, 2001--Warren Jackson, President and Chief Executive Officer of Edmonton-based Altachem Pharma Limited, today announced the successful completion of the formal acquisition of 100% of the world rights to develop, manufacture and sell Bionex(TM), a revolutionary compound desig
EDMONTON, Alberta--(BW HealthWire)--Sept. 26, 2001--Warren Jackson, President and Chief Executive Officer of Edmonton-based Altachem Pharma Limited, today announced the successful completion of the formal acquisition of 100% of the world rights to develop, manufacture and sell Bionex(TM), a revolutionary compound desig
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 25, 2001-- Gilead Sciences (Nasdaq:GILD) today released 24-week efficacy and safety results from a pivotal Phase III study of its investigational one tablet, once daily antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate). The data were to have been presented at t
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 25, 2001-- Gilead Sciences (Nasdaq:GILD) today released 24-week efficacy and safety results from a pivotal Phase III study of its investigational one tablet, once daily antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate). The data were to have been presented at t
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 25, 2001-- Gilead Sciences (Nasdaq:GILD) today released 24-week efficacy and safety results from a pivotal Phase III study of its investigational one tablet, once daily antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate).
FULLERTON, Calif.--(BW HealthWire)--Sept. 25, 2001--A recent study using iTAg(TM) MHC Tetramers from Beckman Coulter, Inc. (NYSE:BEC) found a correlation between the presence of cytomegalovirus ( CMV )-specific T cells and protection from CMV disease in hematopoietic stem cell transplant patients.
FULLERTON, Calif.--(BW HealthWire)--Sept. 25, 2001--A recent study using iTAg(TM) MHC Tetramers from Beckman Coulter, Inc. (NYSE:BEC) found a correlation between the presence of cytomegalovirus ( CMV )-specific T cells and protection from CMV disease in hematopoietic stem cell transplant patients. The results of this s
FULLERTON, Calif.--(BW HealthWire)--Sept. 25, 2001--A recent study using iTAg(TM) MHC Tetramers from Beckman Coulter, Inc. (NYSE:BEC) found a correlation between the presence of cytomegalovirus ( CMV )-specific T cells and protection from CMV disease in hematopoietic stem cell transplant patients. The results of this s
LOS ANGELES--In a landmark advancement for the safety of the nation s supply of plasma derived products, Alpha Therapeutic Corporation today announced it has obtained the first U.S. Food and Drug Administration approval for use of a highly sensitive new testing method for screening plasma donations. The method was deve
LOS ANGELES--In a landmark advancement for the safety of the nation s supply of plasma derived products, Alpha Therapeutic Corporation today announced it has obtained the first U.S. Food and Drug Administration approval for use of a highly sensitive new testing method for screening plasma donations. The method was deve
LOS ANGELES--In a landmark advancement for the safety of the nation s supply of plasma derived products, Alpha Therapeutic Corporation today announced it has obtained the first U.S. Food and Drug Administration approval for use of a highly sensitive new testing method for screening plasma donations. The method was deve
ALAMEDA, Calif.--(BW HealthWire)--Sept. 18, 2001--Calypte Biomedical Corporation announced today progress in their effort to support Community Based Organizations (CBO s), AIDS Service Organizations (ASO s) and Clinics with their painless urine testing alternative. The company has just re-launched its Sentinel(TM) test
ALAMEDA, Calif.--(BW HealthWire)--Sept. 18, 2001--Calypte Biomedical Corporation announced today progress in their effort to support Community Based Organizations (CBO s), AIDS Service Organizations (ASO s) and Clinics with their painless urine testing alternative. The company has just re-launched its Sentinel(TM) test
ALAMEDA, Calif.--(BW HealthWire)--Sept. 18, 2001--Calypte Biomedical Corporation announced today progress in their effort to support Community Based Organizations (CBO s), AIDS Service Organizations (ASO s) and Clinics with their painless urine testing alternative. The company has just re-launched its Sentinel(TM) test
GREENWICH, Conn. & NEW YORK--(BUSINESS WIRE)--Sept. 17, 2001-- Crompton Corporation (NYSE:CK) and The Aaron Diamond AIDS Research Center (ADARC) today announced that Crompton has donated certain intellectual property rights for its UC 781 compound to ADARC for development as a possible anti-HIV therapeutic. UC 781
GREENWICH, Conn. & NEW YORK--(BUSINESS WIRE)--Sept. 17, 2001-- Crompton Corporation (NYSE:CK) and The Aaron Diamond AIDS Research Center (ADARC) today announced that Crompton has donated certain intellectual property rights for its UC 781 compound to ADARC for development as a possible anti-HIV therapeutic. UC 781
GREENWICH, Conn. & NEW YORK--(BUSINESS WIRE)--Sept. 17, 2001-- Crompton Corporation (NYSE:CK) and The Aaron Diamond AIDS Research Center (ADARC) today announced that Crompton has donated certain intellectual property rights for its UC 781 compound to ADARC for development as a possible anti-HIV therapeutic. UC 781
SAN FRANCISCO--(BUSINESS WIRE)--Sept. 14, 2001--Bay Area families are invited to watch some of the world s fastest men and women runners and join in races for children and adults during the Champions Run for Children 2001. The third annual event, 8:30 a.m. to 1:00 p.m. on Sunday, September 16 at Kezar Stadium in San Fr
SAN FRANCISCO--(BUSINESS WIRE)--Sept. 14, 2001--Bay Area families are invited to watch some of the world s fastest men and women runners and join in races for children and adults during the Champions Run for Children 2001. The third annual event, 8:30 a.m. to 1:00 p.m. on Sunday, September 16 at Kezar Stadium in San Fr
SAN FRANCISCO--(BUSINESS WIRE)--Sept. 14, 2001--Bay Area families are invited to watch some of the world s fastest men and women runners and join in races for children and adults during the Champions Run for Children 2001. The third annual event, 8:30 a.m. to 1:00 p.m. on Sunday, September 16 at Kezar Stadium in San Fr
LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001--Aethlon Medical announced today that pre-clinical human blood trials of the company s HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one o
LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001--Aethlon Medical announced today that pre-clinical human blood trials of the company s HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one o
LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001--Aethlon Medical announced today that pre-clinical human blood trials of the company s HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one o
NEWTOWN, Pa.--(BW HealthWire) In the second quarter of 2001, the most often used combination therapy for HIV was Combivir/ Sustiva , which was administered to 12% of patients, according to the HIV Therapy Audit by Scott-Levin, a Quintiles Transnational company (Nasdaq:QTRN).
NEWTOWN, Pa.--(BW HealthWire) In the second quarter of 2001, the most often used combination therapy for HIV was Combivir/ Sustiva , which was administered to 12% of patients, according to the HIV Therapy Audit by Scott-Levin, a Quintiles Transnational company (Nasdaq:QTRN).
NEWTOWN, Pa.--(BW HealthWire) In the second quarter of 2001, the most often used combination therapy for HIV was Combivir / Sustiva , which was administered to 12% of patients, according to the HIV Therapy Audit by
SAN FRANCISCO & PHILADELPHIA--(BW HealthWire)--Sept. 6, 2001--Iguazu Biosciences Corp. announced during the AIDS Vaccine 2001 Conference that it was formed to pursue research, manufacturing and clinical development of a novel generation of HIV vaccines. The company is the exclusive worldwide licensee of a patent ap
SAN FRANCISCO & PHILADELPHIA--(BW HealthWire)--Sept. 6, 2001--Iguazu Biosciences Corp. announced during the AIDS Vaccine 2001 Conference that it was formed to pursue research, manufacturing and clinical development of a novel generation of HIV vaccines. The company is the exclusive worldwide licensee of a patent ap
SAN FRANCISCO & PHILADELPHIA--(BW HealthWire)--Sept. 6, 2001--Iguazu Biosciences Corp. announced during the AIDS Vaccine 2001 Conference that it was formed to pursue research, manufacturing and clinical development of a novel generation of HIV vaccines. The company is the exclusive worldwide licensee of a patent ap
EDMONTON, Alberta & CAPE TOWN, South Africa--(BW Healthwire)--Sept. 5, 2001--Medical Services International Inc. (PINK SHEETS:MSITF) is pleased to announce that it has entered into a joint venture agreement with HIVE Manufacturing and Export (SA) of Cape Town, South Africa. As part of the joint venture HIVE Manufac
EDMONTON, Alberta & CAPE TOWN, South Africa--(BW Healthwire)--Sept. 5, 2001--Medical Services International Inc. (PINK SHEETS:MSITF) is pleased to announce that it has entered into a joint venture agreement with HIVE Manufacturing and Export (SA) of Cape Town, South Africa. As part of the joint venture HIVE Manufac
EDMONTON, Alberta & CAPE TOWN, South Africa--(BW Healthwire)--Sept. 5, 2001--Medical Services International Inc. (PINK SHEETS:MSITF) is pleased to announce that it has entered into a joint venture agreement with HIVE Manufacturing and Export (SA) of Cape Town, South Africa. As part of the joint venture HIVE Manufac
Nutrition 21, Inc. (Nasdaq: NXXI) announced today that the Company s Selenomax(R) High Selenium Yeast is being used as the sole source of selenium in an NIH-funded study of selenium intervention in HIV-infected persons. The study, which has already begun patient enrollment, will be conducted at the University of Miami
Nutrition 21, Inc. (Nasdaq: NXXI) announced today that the Company s Selenomax(R) High Selenium Yeast is being used as the sole source of selenium in an NIH-funded study of selenium intervention in HIV-infected persons. The study, which has already begun patient enrollment, will be conducted at the University of Miami
Nutrition 21, Inc. (Nasdaq: NXXI) announced today that the Company s Selenomax(R) High Selenium Yeast is being used as the sole source of selenium in an NIH-funded study of selenium intervention in HIV-infected persons. The study, which has already begun patient enrollment, will be conducted at the University of Miami
EDMONTON, Alberta--(BW HealthWire)--Aug. 20, 2001--Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, South Africa
EDMONTON, Alberta--(BW HealthWire)--Aug. 20, 2001--Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, South Africa
EDMONTON, Alberta--(BW HealthWire)--Aug. 20, 2001--Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, South Africa
NEW YORK, NY & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2001-- The American Liver Foundation (ALF), the leading national voluntary health organization dedicated to preventing, treating and curing hepatitis and other liver diseases, and Veritas Medicine, a comprehensive online clinical trials and treatment resour
NEW YORK, NY & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2001-- The American Liver Foundation (ALF), the leading national voluntary health organization dedicated to preventing, treating and curing hepatitis and other liver diseases, and Veritas Medicine, a comprehensive online clinical trials and treatment resour
NEW YORK, NY & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2001-- The American Liver Foundation (ALF), the leading national voluntary health organization dedicated to preventing, treating and curing hepatitis and other liver diseases, and Veritas Medicine, a comprehensive online clinical trials and treatment resour
KIRKLAND, Wash.--(BW HealthWire)--Aug. 17, 2001--Cytran announced today that preliminary results of a Phase III clinical trial using IM862 as a monotherapy in AIDS-related Kaposi s sarcoma (KS) did not meet primary efficacy objectives. The Phase III trial reconfirmed the excellent safety and side effect profile IM862 d
KIRKLAND, Wash.--(BW HealthWire)--Aug. 17, 2001--Cytran announced today that preliminary results of a Phase III clinical trial using IM862 as a monotherapy in AIDS-related Kaposi s sarcoma (KS) did not meet primary efficacy objectives. The Phase III trial reconfirmed the excellent safety and side effect profile IM862 d
KIRKLAND, Wash.--(BW HealthWire)--Aug. 17, 2001--Cytran announced today that preliminary results of a Phase III clinical trial using IM862 as a monotherapy in AIDS-related Kaposi s sarcoma (KS) did not meet primary efficacy objectives. The Phase III trial reconfirmed the excellent safety and side effect profile IM862 d
VERNON, Conn.--(BUSINESS WIRE)--Aug. 16, 2001--Bio-Plexus, Inc., (Pink Sheets: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has begun fulfilling customer orders for its PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection. This commercialization follows t
VERNON, Conn.--(BUSINESS WIRE)--Aug. 16, 2001--Bio-Plexus, Inc., (Pink Sheets: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has begun fulfilling customer orders for its PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection. This commercialization follows t
VERNON, Conn.--(BUSINESS WIRE)--Aug. 16, 2001--Bio-Plexus, Inc., (Pink Sheets: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced that it has begun fulfilling customer orders for its PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection. This commercialization follows t
NUTLEY, N.J. and DURHAM, N.C. - Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that both adult pivotal Phase III clinical studies for T-20 are fully enrolled. Approximately 1,000 people living with HIV across Europe, Australia , North America and Brazil are currently participating in studies to eva
NUTLEY, N.J. and DURHAM, N.C. - Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that both adult pivotal Phase III clinical studies for T-20 are fully enrolled. Approximately 1,000 people living with HIV across Europe, Australia , North America and Brazil are currently participating in studies to eva
NUTLEY, N.J. and DURHAM, N.C. - Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that both adult pivotal Phase III clinical studies for T-20 are fully enrolled. Approximately 1,000 people living with HIV across Europe, Australia , North America and Brazil are currently participating in studies to eva
DURHAM, N.C. and BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2001-- Collaboration to target discovery and development of small molecule fusion inhibitors of HIV and RSV Trimeris, Inc. (Nasdaq: TRMS) and Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement to discover small molecule fusion inhibi
DURHAM, N.C. and BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2001-- Collaboration to target discovery and development of small molecule fusion inhibitors of HIV and RSV Trimeris, Inc. (Nasdaq: TRMS) and Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement to discover small molecule fusion inhibi
DURHAM, N.C. and BOULDER, Colo.--(BUSINESS WIRE)--Aug. 6, 2001-- Collaboration to target discovery and development of small molecule fusion inhibitors of HIV and RSV Trimeris, Inc. (Nasdaq: TRMS) and Array BioPharma Inc. (Nasdaq: ARRY) today announced the signing of an agreement to discover small molecule fusion inhibi
SEATTLE--(BUSINESS WIRE)--August 3, 2001-- Kenya Kids AIDS Project, Chapter President Trip Highlight Impact of Local Donations The Seattle Junior Chamber of Commerce (Jaycees) is pleased to announce its initiative to help combat juvenile AIDS in Africa -- Kenya Kids AIDS Project (KKAP) -- will receive international rec
SEATTLE--(BUSINESS WIRE)--August 3, 2001-- Kenya Kids AIDS Project, Chapter President Trip Highlight Impact of Local Donations The Seattle Junior Chamber of Commerce (Jaycees) is pleased to announce its initiative to help combat juvenile AIDS in Africa -- Kenya Kids AIDS Project (KKAP) -- will receive international rec
SEATTLE--(BUSINESS WIRE)--August 3, 2001-- Kenya Kids AIDS Project, Chapter President Trip Highlight Impact of Local Donations The Seattle Junior Chamber of Commerce (Jaycees) is pleased to announce its initiative to help combat juvenile AIDS in Africa -- Kenya Kids AIDS Project (KKAP) -- will receive international rec
NEWTOWN, Pa.--(BW HealthWire)--Aug. 2, 2001-- AIDS Malignancy Consortium Sponsored by the National Cancer Institute Opens a Multi-Center Study to Determine the Response Rate of COL-3 (Metastat(R)) in Patients with HIV-Related Kaposi s Sarcoma CollaGenex Pharmaceuticals (NASDAQ: CGPI) today announced that the AIDS Malig
NEWTOWN, Pa.--(BW HealthWire)--Aug. 2, 2001-- AIDS Malignancy Consortium Sponsored by the National Cancer Institute Opens a Multi-Center Study to Determine the Response Rate of COL-3 (Metastat(R)) in Patients with HIV-Related Kaposi s Sarcoma CollaGenex Pharmaceuticals (NASDAQ: CGPI) today announced that the AIDS Malig
NEWTOWN, Pa.--(BW HealthWire)--Aug. 2, 2001-- AIDS Malignancy Consortium Sponsored by the National Cancer Institute Opens a Multi-Center Study to Determine the Response Rate of COL-3 (Metastat(R)) in Patients with HIV-Related Kaposi s Sarcoma CollaGenex Pharmaceuticals (NASDAQ: CGPI) today announced that the AIDS Malig
ALAMEDA, Calif.--(BW HealthWire)--July 31, 2001--Celera Diagnostics, a joint venture of Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA), Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the U.S. Food and Drug Administration, seeking marketing
ALAMEDA, Calif.--(BW HealthWire)--July 31, 2001--Celera Diagnostics, a joint venture of Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA), Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the U.S. Food and Drug Administration, seeking marketing
ALAMEDA, Calif.--(BW HealthWire)--July 31, 2001--Celera Diagnostics, a joint venture of Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA), Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the U.S. Food and Drug Administration, seeking marketing
SAN DIEGO--(BW HealthWire)--June 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlin
SAN DIEGO--(BW HealthWire)--June 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlin
SAN DIEGO--(BW HealthWire)--June 25, 2001--Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) announced today that United States Patent number 6,265,539 entitled Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome has been issued to the Board of Regents of The University of Texas. The inventor is Dr. Ralph Arlin
CALCOL INC. (OTC:CLCL) a development stage U.S. holding company for China manufacturing companies in pharmaceuticals (Calcol Changbaishan Pharmaceutical Ltd. Shenzhen, China) and soft drinks (Sanhe Meile Soft Drinks Ltd. Beijing, China), announced today that it has signed a binding letter of intent effective July 19, 2
CALCOL INC. (OTC:CLCL) a development stage U.S. holding company for China manufacturing companies in pharmaceuticals (Calcol Changbaishan Pharmaceutical Ltd. Shenzhen, China) and soft drinks (Sanhe Meile Soft Drinks Ltd. Beijing, China), announced today that it has signed a binding letter of intent effective July 19, 2
CALCOL INC. (OTC:CLCL) a development stage U.S. holding company for China manufacturing companies in pharmaceuticals (Calcol Changbaishan Pharmaceutical Ltd. Shenzhen, China) and soft drinks (Sanhe Meile Soft Drinks Ltd. Beijing, China), announced today that it has signed a binding letter of intent effective July 19, 2
LARCHMONT, N.Y.--In a study of more than a thousand heterosexual couples in sub-Saharan Africa, where over 80% of the world s HIV-infected adults live, a team of researchers from the University of Alabama at Birmingham (UAB) working with scientists in Zambia found that the risk of transmission of HIV-1 between the sexe
LARCHMONT, N.Y.--In a study of more than a thousand heterosexual couples in sub-Saharan Africa, where over 80% of the world s HIV-infected adults live, a team of researchers from the University of Alabama at Birmingham (UAB) working with scientists in Zambia found that the risk of transmission of HIV-1 between the sexe
LARCHMONT, N.Y.--In a study of more than a thousand heterosexual couples in sub-Saharan Africa, where over 80% of the world s HIV-infected adults live, a team of researchers from the University of Alabama at Birmingham (UAB) working with scientists in Zambia found that the risk of transmission of HIV-1 between the sexe
SAN ANTONIO--(BW HealthWire)--July 18, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans.
SAN ANTONIO--(BW HealthWire)--July 18, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans.
SAN ANTONIO--(BW HealthWire)--July 18, 2001--Esoterix Infectious Disease Center announced the launch of HIVComplete(tm), a new weapon in the fight against AIDS. HIVComplete is the first comprehensive testing and information service focused on the management of HIV, a disease infecting nearly one million Americans.
YONKERS, N.Y.--July 17, 2001--Advanced Viral Research Corp. (OTCBB: ADVR) today announced the publication of a scientific research paper showing that Product R, the Company s peptide-nucleic acid immunomodulator, enhances the production of two proteins that boost the immune response during viral infection. The paper, e
YONKERS, N.Y.--July 17, 2001--Advanced Viral Research Corp. (OTCBB: ADVR) today announced the publication of a scientific research paper showing that Product R, the Company s peptide-nucleic acid immunomodulator, enhances the production of two proteins that boost the immune response during viral infection. The paper, e
YONKERS, N.Y.--July 17, 2001--Advanced Viral Research Corp. (OTCBB: ADVR) today announced the publication of a scientific research paper showing that Product R, the Company s peptide-nucleic acid immunomodulator, enhances the production of two proteins that boost the immune response during viral infection. The paper, e
MONTREAL--Franc-Or Resources Corporation (TSE:FOR.) is pleased to announce that URRMA Biopharma Inc., a private Montreal-based biotech company into which the Company recently invested $2 million, has completed construction of a new research laboratory in Aubagne, France , near Marseille. The opening ceremony on Jul
MONTREAL--Franc-Or Resources Corporation (TSE:FOR.) is pleased to announce that URRMA Biopharma Inc., a private Montreal-based biotech company into which the Company recently invested $2 million, has completed construction of a new research laboratory in Aubagne, France , near Marseille. The opening ceremony on Jul
MONTREAL--Franc-Or Resources Corporation (TSE:FOR.) is pleased to announce that URRMA Biopharma Inc., a private Montreal-based biotech company into which the Company recently invested $2 million, has completed construction of a new research laboratory in Aubagne, France , near Marseille. The opening ceremony on Jul
PHILADELPHIA--Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today a strategic partnership with Empire Health Resources, the nation s leading privately held healthcare ma
PHILADELPHIA--Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today a strategic partnership with Empire Health Resources, the nation s leading privately held healthcare ma
PHILADELPHIA--Hemispherx Biopharma, Inc. (AMEX: HEB), a leading biopharmaceutical company specializing in the development of nucleic acids (NA) to enhance anti-viral defense systems in the human body, announced today a strategic partnership with Empire Health Resources, the nation s leading privately held healthcare ma
BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that has filed with the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes,
BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that has filed with the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes,
BETHLEHEM, Pa.--(BW HealthWire)--July 11, 2001--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that has filed with the U.S. Food and Drug Administration ( FDA ) for Pre-Market Approval of its OraQuick(R) HIV test. OraQuick is a rapid test device that can detect antibodies to the HIV disease within 20 minutes,
BUENOS AIRES, Argentina--(BW HealthWire)--July 11, 2001--Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference
BUENOS AIRES, Argentina--(BW HealthWire)--July 11, 2001--Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference
BUENOS AIRES, Argentina--(BW HealthWire)--July 11, 2001--Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference
CORRECTION...by Trimeris NOTE: The following news release replaces and corrects the previous Trimeris news release which ran earlier Thursday on Business Wire, BW2100 (NJ-TRIMERIS/ROCHE) NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--June 28, 2001--Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced the completi
CORRECTION...by Trimeris NOTE: The following news release replaces and corrects the previous Trimeris news release which ran earlier Thursday on Business Wire, BW2100 (NJ-TRIMERIS/ROCHE) NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--June 28, 2001--Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced the completi
CORRECTION...by Trimeris NOTE: The following news release replaces and corrects the previous Trimeris news release which ran earlier Thursday on Business Wire, BW2100 (NJ-TRIMERIS/ROCHE) NUTLEY, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--June 28, 2001--Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced the completi
ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration ( FDA ) has approved Calypte s premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot. Calypte envisions a number o
ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration ( FDA ) has approved Calypte s premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot. Calypte envisions a number o
ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration ( FDA ) has approved Calypte s premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot. Calypte envisions a number o
VERNON HILLS, Ill.--(BW HealthWire)--June 21, 2001--Immtech International, Inc., (NASDAQ NMS:IMMT), a biopharmaceutical company focused on the discovery and commercialization of drugs for the treatment of fungal diseases, tuberculosis , hepatitis, pneumonia, diarrhea, and cancer, announced today that Dr. Scott Franzbla
VERNON HILLS, Ill.--(BW HealthWire)--June 21, 2001--Immtech International, Inc., (NASDAQ NMS:IMMT), a biopharmaceutical company focused on the discovery and commercialization of drugs for the treatment of fungal diseases, tuberculosis , hepatitis , pneumonia, diarrhea, and cancer, announced today that Dr.
VERNON HILLS, Ill.--(BW HealthWire)--June 21, 2001--Immtech International, Inc., (NASDAQ NMS:IMMT), a biopharmaceutical company focused on the discovery and commercialization of drugs for the treatment of fungal diseases, tuberculosis , hepatitis , pneumonia, diarrhea, and cancer, announced today that Dr.
NUTLEY, N.J. & DURHAM, N.C.--(BW HealthWire)--June 19, 2001--Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two comp
NUTLEY, N.J. & DURHAM, N.C.--(BW HealthWire)--June 19, 2001--Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two comp
NUTLEY, N.J. & DURHAM, N.C.--(BW HealthWire)--June 19, 2001--Roche and Trimeris, Inc. announced today the signing of a research agreement to discover, develop and commercialize novel generations of HIV fusion inhibitor peptides. This agreement expands upon a 1999 worldwide partnership agreement between the two comp
FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001--The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial involving a new approach to treating human immunedeficiency virus (HIV) infection. The study will involve using immune-based therapy with the medication Ampli
FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001--The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial involving a new approach to treating human immunedeficiency virus (HIV) infection. The study will involve using immune-based therapy with the medication Ampli
FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001--The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial involving a new approach to treating human immunedeficiency virus (HIV) infection. The study will involve using immune-based therapy with the medication Ampli
SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (
SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (
SAN DIEGO--(BW HealthWire)--June 5, 2001--Epicyte Pharmaceutical Inc. today announced that the Company has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for the development of antibodies to prevent the transmission of human papillomavirus (
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--June 5, 2001-- Gilead Sciences , Inc. today presented in vitro data further characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company s investigational agent in development for the potential treatment of HIV infection. The resistance profile o
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--June 5, 2001-- Gilead Sciences , Inc. today presented in vitro data further characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company s investigational agent in development for the potential treatment of HIV infection. The resistance profile o
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--June 5, 2001-- Gilead Sciences , Inc. today presented in vitro data further characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company s investigational agent in development for the potential treatment of HIV infection. The resistance profile o
CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
STANFORD, Calif.--(BUSINESS WIRE)--June 1, 2001--For many years, AIDS care and treatment in Africa has long been dismissed as unfeasible -- the drug therapies too expensive, the health care infrastructure too inadequate and the infection rate too great. But a Stanford University Medical Center researcher who has spent
STANFORD, Calif.--(BUSINESS WIRE)--June 1, 2001--For many years, AIDS care and treatment in Africa has long been dismissed as unfeasible -- the drug therapies too expensive, the health care infrastructure too inadequate and the infection rate too great. But a Stanford University Medical Center researcher who has spent
STANFORD, Calif.--(BUSINESS WIRE)--June 1, 2001--For many years, AIDS care and treatment in Africa has long been dismissed as unfeasible -- the drug therapies too expensive, the health care infrastructure too inadequate and the infection rate too great. But a Stanford University Medical Center researcher who has spent
CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
CARLSBAD, Calif.--(BUSINESS WIRE)--June 1, 2001--The Immune Response Corporation (NASDAQ:IMNR) announced today that an independent Data Safety Monitoring Board (DSMB) has evaluated the results from a phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigational immune-base
SAN FRANCISCO--(BW HealthWire)--May 30, 2001--Coinciding with the 20th year of AIDS, the California Department of Health Services, Office of AIDS (CDHS-OA) will announce the availability of updated, church-sensitive HIV/AIDS outreach material. They include a new interactive HIV/AIDS Quiz Card and Getting Started supple
SAN FRANCISCO--(BW HealthWire)--May 30, 2001--Coinciding with the 20th year of AIDS, the California Department of Health Services, Office of AIDS (CDHS-OA) will announce the availability of updated, church-sensitive HIV/AIDS outreach material. They include a new interactive HIV/AIDS Quiz Card and Getting Started supple
SAN FRANCISCO--(BW HealthWire)--May 30, 2001--Coinciding with the 20th year of AIDS, the California Department of Health Services, Office of AIDS (CDHS-OA) will announce the availability of updated, church-sensitive HIV/AIDS outreach material. They include a new interactive HIV/AIDS Quiz Card and Getting Started supple
GREENWICH, Conn. & PHILADELPHIA--(BUSINESS WIRE)--May 23, 2001-- Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling ne
GREENWICH, Conn. & PHILADELPHIA--(BUSINESS WIRE)--May 23, 2001-- Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling ne
GREENWICH, Conn. & PHILADELPHIA--(BUSINESS WIRE)--May 23, 2001-- Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling ne
PHILADELPHIA--(BUSINESS WIRE)--May 10, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) commenced today a recently FDA authorized Phase IIb protocol designed to accelerate immunologic gains in patients receiving intense antiviral therapy for HIV disease. The objectives of the new protocol, which will enroll over 100
PHILADELPHIA--(BUSINESS WIRE)--May 10, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) commenced today a recently FDA authorized Phase IIb protocol designed to accelerate immunologic gains in patients receiving intense antiviral therapy for HIV disease. The objectives of the new protocol, which will enroll over 100
PHILADELPHIA--(BUSINESS WIRE)--May 10, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) commenced today a recently FDA authorized Phase IIb protocol designed to accelerate immunologic gains in patients receiving intense antiviral therapy for HIV disease. The objectives of the new protocol, which will enroll over 100
NEW YORK--(BW HealthWire)--May 8, 2001--The NY Daily News reported yesterday on the potential of Atlantic Technology Ventures, Inc. s (NASDAQ:ATLC) CT-3 as a therapy that circumvents the political stigma associated with patients smoking marijuana to reduce side effects resulting from chemotherapy, arthritis, AIDS, seve
NEW YORK--(BW HealthWire)--May 8, 2001--The NY Daily News reported yesterday on the potential of Atlantic Technology Ventures, Inc. s (NASDAQ:ATLC) CT-3 as a therapy that circumvents the political stigma associated with patients smoking marijuana to reduce side effects resulting from chemotherapy, arthritis, AIDS, seve
NEW YORK--(BW HealthWire)--May 8, 2001--The NY Daily News reported yesterday on the potential of Atlantic Technology Ventures, Inc. s (NASDAQ:ATLC) CT-3 as a therapy that circumvents the political stigma associated with patients smoking marijuana to reduce side effects resulting from chemotherapy, arthritis, AIDS, seve
SOMERVILLE, Mass.--(BW HealthWire)--May 7, 2001--New research, presented May 4 at the College of Reproductive Biology, American Association of Bioanalysts meeting, Las Vegas, NV has provided HIV infected men a potential new option for safe procreation. Dr. Hui-Zhong Yin presented results of a study of 30 HIV infected m
SOMERVILLE, Mass.--(BW HealthWire)--May 7, 2001--New research, presented May 4 at the College of Reproductive Biology, American Association of Bioanalysts meeting, Las Vegas, NV has provided HIV infected men a potential new option for safe procreation. Dr. Hui-Zhong Yin presented results of a study of 30 HIV infected m
SOMERVILLE, Mass.--(BW HealthWire)--May 7, 2001--New research, presented May 4 at the College of Reproductive Biology, American Association of Bioanalysts meeting, Las Vegas, NV has provided HIV infected men a potential new option for safe procreation. Dr. Hui-Zhong Yin presented results of a study of 30 HIV infected m
LA JOLLA, Calif.--(BW HealthWire)--May 1, 2001--Aethlon Medical (OTCBB:AEMD) announced today that the company s HIV-Hemopurifier(TM) was the subject of a feature science story that was released by United Press International (UPI) Saturday, April 28, 2001. Following is the story in its entirety and is reprinted with per
LA JOLLA, Calif.--(BW HealthWire)--May 1, 2001--Aethlon Medical (OTCBB:AEMD) announced today that the company s HIV-Hemopurifier(TM) was the subject of a feature science story that was released by United Press International (UPI) Saturday, April 28, 2001. Following is the story in its entirety and is reprinted with per
LA JOLLA, Calif.--(BW HealthWire)--May 1, 2001--Aethlon Medical (OTCBB:AEMD) announced today that the company s HIV-Hemopurifier(TM) was the subject of a feature science story that was released by United Press International (UPI) Saturday, April 28, 2001. Following is the story in its entirety and is reprinted with per
COLUMBIA, Md.--(BUSINESS WIRE)--April 20, 2001--Cylex Inc., a Columbia, Maryland based diagnostic Company, announced it has received a Phase II Maryland Industrial Partnership (MIPS) Award in the amount of $69,218 for its project, Assay System for Measuring Immune Reconstitution. The Company is collaborating with Rober
COLUMBIA, Md.--(BUSINESS WIRE)--April 20, 2001--Cylex Inc., a Columbia, Maryland based diagnostic Company, announced it has received a Phase II Maryland Industrial Partnership (MIPS) Award in the amount of $69,218 for its project, Assay System for Measuring Immune Reconstitution. The Company is collaborating with Rober
COLUMBIA, Md.--(BUSINESS WIRE)--April 20, 2001--Cylex Inc., a Columbia, Maryland based diagnostic Company, announced it has received a Phase II Maryland Industrial Partnership (MIPS) Award in the amount of $69,218 for its project, Assay System for Measuring Immune Reconstitution. The Company is collaborating with Rober
LOS ANGELES--(BUSINESS WIRE)--April 18, 2001--Kaire Holdings, Inc. (OTCBB:KAHI) announced today that it plans to expand its senior and HIV Health Advocate Programs. The Program currently operates in Los Angeles, but the company plans to expand into Orange, San Diego and San Bernardino counties in southern California.
LOS ANGELES--(BUSINESS WIRE)--April 18, 2001--Kaire Holdings, Inc. (OTCBB:KAHI) announced today that it plans to expand its senior and HIV Health Advocate Programs. The Program currently operates in Los Angeles, but the company plans to expand into Orange, San Diego and San Bernardino counties in southern California.
LOS ANGELES--(BUSINESS WIRE)--April 18, 2001--Kaire Holdings, Inc. (OTCBB:KAHI) announced today that it plans to expand its senior and HIV Health Advocate Programs. The Program currently operates in Los Angeles, but the company plans to expand into Orange, San Diego and San Bernardino counties in southern California.
NEWTOWN, Pa.--(BW HealthWire)--April 13, 2001--Since the onset of the AIDS epidemic 15 years ago, HIV has infected more than 47 million people globally, according to the World Health Organization . AIDS now is the fourth-leading cause of mortality worldwide. The spring 2001 issue of Scott-Levin s Pharmaceutical Quarter
NEWTOWN, Pa.--(BW HealthWire)--April 13, 2001--Since the onset of the AIDS epidemic 15 years ago, HIV has infected more than 47 million people globally, according to the World Health Organization . AIDS now is the fourth-leading cause of mortality worldwide. The spring 2001 issue of Scott-Levin s Pharmaceutical Quarter
NEWTOWN, Pa.--(BW HealthWire)--April 13, 2001--Since the onset of the AIDS epidemic 15 years ago, HIV has infected more than 47 million people globally, according to the World Health Organization . AIDS now is the fourth-leading cause of mortality worldwide. The spring 2001 issue of Scott-Levin s Pharmaceutical Quarter
BETHLEHEM, Penn.--(BW HealthWire)--April 4, 2001--OraSure Technologies, Inc. announced that the company has received an initial order from the Centers for Disease Control for 118,000 OraQuick(R) HIV-1/2 devices, in conjunction with the LIFE (Leadership and Investment in Fighting an Epidemic) Initiative. OraQuick HIV-1/
BETHLEHEM, Penn.--(BW HealthWire)--April 4, 2001--OraSure Technologies, Inc. announced that the company has received an initial order from the Centers for Disease Control for 118,000 OraQuick(R) HIV-1/2 devices, in conjunction with the LIFE (Leadership and Investment in Fighting an Epidemic) Initiative. OraQuick HIV-1/
BETHLEHEM, Penn.--(BW HealthWire)--April 4, 2001--OraSure Technologies, Inc. announced that the company has received an initial order from the Centers for Disease Control for 118,000 OraQuick(R) HIV-1/2 devices, in conjunction with the LIFE (Leadership and Investment in Fighting an Epidemic) Initiative. OraQuick HIV-1/
SEATTLE--(BW HealthWire)--March 30, 2001--Targeted Genetics Corporation (Nasdaq:TGEN) today will announce promising data from preclinical studies utilizing recombinant adeno-associated virus (AAV) vectors as a form of vaccination. Data will be presented by Philip R. Johnson, M.D., President of the Children s Research I
SEATTLE--(BW HealthWire)--March 30, 2001--Targeted Genetics Corporation (Nasdaq:TGEN) today will announce promising data from preclinical studies utilizing recombinant adeno-associated virus (AAV) vectors as a form of vaccination. Data will be presented by Philip R. Johnson, M.D., President of the Children s Research I
SEATTLE--(BW HealthWire)--March 30, 2001--Targeted Genetics Corporation (Nasdaq:TGEN) today will announce promising data from preclinical studies utilizing recombinant adeno-associated virus (AAV) vectors as a form of vaccination. Data will be presented by Philip R. Johnson, M.D., President of the Children s Research I
PHILADELPHIA--(BUSINESS WIRE)--March 29, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB;HEBws) and AIDS Research Alliance, a non-profit clinical research organization based in West Hollywood, California, announced today a new research agreement. Under terms of the letter of understanding, AIDS Research Alliance will provi
PHILADELPHIA--(BUSINESS WIRE)--March 29, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB;HEBws) and AIDS Research Alliance, a non-profit clinical research organization based in West Hollywood, California, announced today a new research agreement. Under terms of the letter of understanding, AIDS Research Alliance will provi
PHILADELPHIA--(BUSINESS WIRE)--March 29, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB;HEBws) and AIDS Research Alliance, a non-profit clinical research organization based in West Hollywood, California, announced today a new research agreement. Under terms of the letter of understanding, AIDS Research Alliance will provi
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--March 26, 2001-- ViroLogic Inc. (Nasdaq:VLGC) today announced an agreement with Chiron Corporation to assist in clinical evaluation of new anti-HIV agents in development at Chiron. Chiron will use ViroLogic s phenotypic drug resistance test, PhenoSense HIV, to assess drug a
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--March 26, 2001-- ViroLogic Inc. (Nasdaq:VLGC) today announced an agreement with Chiron Corporation to assist in clinical evaluation of new anti-HIV agents in development at Chiron. Chiron will use ViroLogic s phenotypic drug resistance test, PhenoSense HIV, to assess drug a
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--March 26, 2001-- ViroLogic Inc. (Nasdaq:VLGC) today announced an agreement with Chiron Corporation to assist in clinical evaluation of new anti-HIV agents in development at Chiron. Chiron will use ViroLogic s phenotypic drug resistance test, PhenoSense HIV, to assess drug a
SAN FRANCISCO--(BW HealthWire)--March 2, 2001--The 13th annual National HIV/AIDS Update Conference (NAUC) -- organized by the American Foundation for AIDS Research (amfAR) -- will highlight new drug regimens for people with HIV/AIDS. NAUC adds an international voice this year, with presentations by AIDS experts from se
SAN FRANCISCO--(BW HealthWire)--March 2, 2001--The 13th annual National HIV/AIDS Update Conference (NAUC) -- organized by the American Foundation for AIDS Research (amfAR) -- will highlight new drug regimens for people with HIV/AIDS. NAUC adds an international voice this year, with presentations by AIDS experts from se
SAN FRANCISCO--(BW HealthWire)--March 2, 2001--The 13th annual National HIV/AIDS Update Conference (NAUC) -- organized by the American Foundation for AIDS Research (amfAR) -- will highlight new drug regimens for people with HIV/AIDS. NAUC adds an international voice this year, with presentations by AIDS experts from se
Trimeris, Inc. (Nasdaq: TRMS) and Hoffmann-La Roche today provide a brief summary of data on the investigational agents T-20 and T-1249, the first in a new class of anti-HIV compounds known as fusion inhibitors. The preliminary data were presented this week over several sessions at the Eighth Annual Conference on Retro
Trimeris, Inc. (Nasdaq: TRMS) and Hoffmann-La Roche today provide a brief summary of data on the investigational agents T-20 and T-1249, the first in a new class of anti-HIV compounds known as fusion inhibitors. The preliminary data were presented this week over several sessions at the Eighth Annual Conference on Retro
Trimeris, Inc. (Nasdaq: TRMS) and Hoffmann-La Roche today provide a brief summary of data on the investigational agents T-20 and T-1249, the first in a new class of anti-HIV compounds known as fusion inhibitors. The preliminary data were presented this week over several sessions at the Eighth Annual Conference on Retro
LAS VEGAS--(BW HealthWire)--Feb. 7, 2001--Samaritan Pharmaceuticals (OTCBB:SPHC) announced that its FDA Phase Ib/IIa safety and efficacy clinical trials under its IND for Anticort(TM) (an HIV/AIDS indication) at the Aids Research Alliance located in Los Angeles, are expected to be completed at the end of March or early
LAS VEGAS--(BW HealthWire)--Feb. 7, 2001--Samaritan Pharmaceuticals (OTCBB:SPHC) announced that its FDA Phase Ib/IIa safety and efficacy clinical trials under its IND for Anticort(TM) (an HIV/AIDS indication) at the Aids Research Alliance located in Los Angeles, are expected to be completed at the end of March or early
LAS VEGAS--(BW HealthWire)--Feb. 7, 2001--Samaritan Pharmaceuticals (OTCBB:SPHC) announced that its FDA Phase Ib/IIa safety and efficacy clinical trials under its IND for Anticort(TM) (an HIV/AIDS indication) at the Aids Research Alliance located in Los Angeles, are expected to be completed at the end of March or early
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2001-- Calypte Biomedical Corporation (NASDAQ: CALY) announced today that beginning this month, Organon Teknika Corporation, a leader in the field of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical.
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2001-- Calypte Biomedical Corporation (NASDAQ: CALY) announced today that beginning this month, Organon Teknika Corporation, a leader in the field of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical.
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2001-- Calypte Biomedical Corporation (NASDAQ: CALY) announced today that beginning this month, Organon Teknika Corporation, a leader in the field of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical.
Enzo Biochem, Inc. (NYSE:ENZ) has achieved the first successful autologous stem cell gene therapy conducted in HIV-infected adults, Dean L. Engelhardt, Ph.D., Executive Vice President, today reported at the 8th Conference on Retroviruses and Opportunistic Infections, in Chicago, IL. His comment was made in a presentati
Enzo Biochem, Inc. (NYSE:ENZ) has achieved the first successful autologous stem cell gene therapy conducted in HIV-infected adults, Dean L. Engelhardt, Ph.D., Executive Vice President, today reported at the 8th Conference on Retroviruses and Opportunistic Infections, in Chicago, IL. His comment was made in a presentati
Enzo Biochem, Inc. (NYSE:ENZ) has achieved the first successful autologous stem cell gene therapy conducted in HIV-infected adults, Dean L. Engelhardt, Ph.D., Executive Vice President, today reported at the 8th Conference on Retroviruses and Opportunistic Infections, in Chicago, IL. His comment was made in a presentati
SEATTLE--(BW HealthWire)--Jan. 29, 2001--Corixa Corporation , a research- and development-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering certain compositions and methods for inducing an immune response using chemokine rece
SEATTLE--(BW HealthWire)--Jan. 29, 2001--Corixa Corporation , a research- and development-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering certain compositions and methods for inducing an immune response using chemokine rece
SEATTLE--(BW HealthWire)--Jan. 29, 2001--Corixa Corporation , a research- and development-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a patent covering certain compositions and methods for inducing an immune response using chemokine rece
SANTA CLARA, Calif. & DAVOS, Switzerland--(BUSINESS WIRE)--Jan. 27, 2001-- Global Internet Leader Yahoo! is the First Major Corporate Supporter of The International AIDS Vaccine Initiative (IAVI) Yahoo! Inc. (Nasdaq:YHOO), a global Internet commerce, communications and media company, today pledged US$5 million to s
SANTA CLARA, Calif. & DAVOS, Switzerland--(BUSINESS WIRE)--Jan. 27, 2001-- Global Internet Leader Yahoo! is the First Major Corporate Supporter of The International AIDS Vaccine Initiative (IAVI) Yahoo! Inc. (Nasdaq:YHOO), a global Internet commerce, communications and media company, today pledged US$5 million to s
SANTA CLARA, Calif. & DAVOS, Switzerland--(BUSINESS WIRE)--Jan. 27, 2001-- Global Internet Leader Yahoo! is the First Major Corporate Supporter of The International AIDS Vaccine Initiative (IAVI) Yahoo! Inc. (Nasdaq:YHOO), a global Internet commerce, communications and media company, today pledged US$5 million to s
PLEASANTON, Calif.--(BW HealthWire)--Jan. 26, 2001--The Technical Board of Appeals of the European Patent Office in Munich, Germany has issued an intermediate decision earlier today, finding that the claims stemming from European Patent EP 181 150 by Chiron Corporation can be upheld only in modified form. The patent cl
PLEASANTON, Calif.--(BW HealthWire)--Jan. 26, 2001--The Technical Board of Appeals of the European Patent Office in Munich, Germany has issued an intermediate decision earlier today, finding that the claims stemming from European Patent EP 181 150 by Chiron Corporation can be upheld only in modified form. The patent cl
PLEASANTON, Calif.--(BW HealthWire)--Jan. 26, 2001--The Technical Board of Appeals of the European Patent Office in Munich, Germany has issued an intermediate decision earlier today, finding that the claims stemming from European Patent EP 181 150 by Chiron Corporation can be upheld only in modified form. The patent cl
FOSTER CITY, Calif.--(BW HealthWire)--Jan. 24, 2001-- Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, announced today that the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research has approved an Investigational Device Exemption (IDE) for the ViroSeq(TM) HIV-1 Genotypin
FOSTER CITY, Calif.--(BW HealthWire)--Jan. 24, 2001-- Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, announced today that the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research has approved an Investigational Device Exemption (IDE) for the ViroSeq(TM) HIV-1 Genotypin
FOSTER CITY, Calif.--(BW HealthWire)--Jan. 24, 2001-- Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, announced today that the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research has approved an Investigational Device Exemption (IDE) for the ViroSeq(TM) HIV-1 Genotypin
LOS ANGELES--(BUSINESS WIRE)--Jan. 22, 2001-- Public/Private Partnership Will Provide Genotypic Testing With Visible Genetics TRUGENE(TM) HIV-1 Genotyping Technology Under Vigilance II Study The Los Angeles County Department of Health Services (DHS) will begin providing state-of-the-art genotypic testing for low-income
LOS ANGELES--(BUSINESS WIRE)--Jan. 22, 2001-- Public/Private Partnership Will Provide Genotypic Testing With Visible Genetics TRUGENE(TM) HIV-1 Genotyping Technology Under Vigilance II Study The Los Angeles County Department of Health Services (DHS) will begin providing state-of-the-art genotypic testing for low-income
LOS ANGELES--(BUSINESS WIRE)--Jan. 22, 2001-- Public/Private Partnership Will Provide Genotypic Testing With Visible Genetics TRUGENE(TM) HIV-1 Genotyping Technology Under Vigilance II Study The Los Angeles County Department of Health Services (DHS) will begin providing state-of-the-art genotypic testing for low-income
ViroLogic, Inc. (NASDAQ: VLGC) today announced preliminary results from a clinical trial of its PhenoSense(TM) HIV drug resistance test. While the trial results showed no difference in the primary endpoints of the study, the trial uncovered significant new information that will improve the use of the assay in guiding p
ViroLogic, Inc. (NASDAQ: VLGC) today announced preliminary results from a clinical trial of its PhenoSense(TM) HIV drug resistance test. While the trial results showed no difference in the primary endpoints of the study, the trial uncovered significant new information that will improve the use of the assay in guiding p
ViroLogic, Inc. (NASDAQ: VLGC) today announced preliminary results from a clinical trial of its PhenoSense(TM) HIV drug resistance test. While the trial results showed no difference in the primary endpoints of the study, the trial uncovered significant new information that will improve the use of the assay in guiding p
PLEASANTON, Calif.--(BUSINESS WIRE)--Jan. 30, 2001--Roche Molecular Systems announced today that its new automated, viral load in vitro diagnostic test for HIV-1 has been accepted for review by the U.S. Food and Drug Administration ( FDA ). This assay, called the COBAS AMPLICOR HIV-1 MONITOR(TM) Test, version 1.5, uses
PLEASANTON, Calif.--(BUSINESS WIRE)--Jan. 30, 2001--Roche Molecular Systems announced today that its new automated, viral load in vitro diagnostic test for HIV-1 has been accepted for review by the U.S. Food and Drug Administration ( FDA ). This assay, called the COBAS AMPLICOR HIV-1 MONITOR(TM) Test, version 1.5, uses
PLEASANTON, Calif.--(BUSINESS WIRE)--Jan. 30, 2001--Roche Molecular Systems announced today that its new automated, viral load in vitro diagnostic test for HIV-1 has been accepted for review by the U.S. Food and Drug Administration ( FDA ). This assay, called the COBAS AMPLICOR HIV-1 MONITOR(TM) Test, version 1.5, uses
PHILADELPHIA--(BUSINESS WIRE)--Jan. 29, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) announced today a major amendment in a recent FDA authorized Phase II protocol designed to accelerate immunologic gains in patients receiving intensified antiviral therapy for HIV disease. The objectives of the new protocol are
PHILADELPHIA--(BUSINESS WIRE)--Jan. 29, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) announced today a major amendment in a recent FDA authorized Phase II protocol designed to accelerate immunologic gains in patients receiving intensified antiviral therapy for HIV disease. The objectives of the new protocol are
PHILADELPHIA--(BUSINESS WIRE)--Jan. 29, 2001--Hemispherx Biopharma, Inc. (AMEX: HEB; HEBws) announced today a major amendment in a recent FDA authorized Phase II protocol designed to accelerate immunologic gains in patients receiving intensified antiviral therapy for HIV disease. The objectives of the new protocol are
DURHAM, N.C. and NUTLEY, N.J.--(BW HealthWire)--January 29, 2001-- Trimeris, Inc. and Hoffmann-La Roche announced results today from several clinical trials with T-20 and T-1249, the first members of a new class of anti-HIV drugs called fusion inhibitors. The results to be presented at an upcoming scientific conference
DURHAM, N.C. and NUTLEY, N.J.--(BW HealthWire)--January 29, 2001-- Trimeris, Inc. and Hoffmann-La Roche announced results today from several clinical trials with T-20 and T-1249, the first members of a new class of anti-HIV drugs called fusion inhibitors. The results to be presented at an upcoming scientific conference
DURHAM, N.C. and NUTLEY, N.J.--(BW HealthWire)--January 29, 2001-- Trimeris, Inc. and Hoffmann-La Roche announced results today from several clinical trials with T-20 and T-1249, the first members of a new class of anti-HIV drugs called fusion inhibitors. The results to be presented at an upcoming scientific conference
PHILADELPHIA, Pa.--(BUSINESS WIRE)--Jan. 3, 2001--Hemispherx Biopharma, Inc. (AMEX:HEB) announced today a newly reviewed FDA clinical protocol designed to test the blunting of the emergence of drug-resistant HIV strains. The new Ampligen(R) investigational protocol will be implemented side-by-side with another recently
PHILADELPHIA, Pa.--(BUSINESS WIRE)--Jan. 3, 2001--Hemispherx Biopharma, Inc. (AMEX:HEB) announced today a newly reviewed FDA clinical protocol designed to test the blunting of the emergence of drug-resistant HIV strains. The new Ampligen(R) investigational protocol will be implemented side-by-side with another recently
PHILADELPHIA, Pa.--(BUSINESS WIRE)--Jan. 3, 2001--Hemispherx Biopharma, Inc. (AMEX:HEB) announced today a newly reviewed FDA clinical protocol designed to test the blunting of the emergence of drug-resistant HIV strains. The new Ampligen(R) investigational protocol will be implemented side-by-side with another recently
This information is designed to support, not replace, the relationship that exists between you and your doctor.